You are here: Home » Companies » News
Business Standard

Unichem Labs gets USFDA nod to market capsules to treat osteoarthritis

Drug firmUnichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules

Topics
Unichem Labs

Press Trust of India  |  New Delhi 

MNCs raise concerns around the definition of inventions, provisions for compulsory licensing

Drug firmUnichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules used for treatment of osteoarthritis, rheumatoid arthritis and acute pain.

The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United StatesFood and Drug Administration (USFDA),Unichem said in a filing to BSE.

The capsules are generic versions of GD Searle LLC's Celebrexcapsules in the same strengths, it added.

The product will be commercialized from the company's Goa plant, the filing said.

"Celecoxib capsules are indicated for treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea," it added.

Shares of Unichem Laboratories were trading at Rs 280.55 per scrip on BSE, up 1.04 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 13 2021. 13:53 IST
RECOMMENDED FOR YOU
.